181 related articles for article (PubMed ID: 38016139)
1. Predicting recurrence and survival in patients with non-metastatic renal-cell carcinoma after nephrectomy: a prospective population-based study with multicenter validation.
Wang Y; Xuan Y; Su B; Gao Y; Fan Y; Huang Q; Zhang P; Gu L; Niu S; Shen D; Li X; Wang B; Zhu Q; Ouyang Z; Xie J; Ma X
Int J Surg; 2024 Feb; 110(2):820-831. PubMed ID: 38016139
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a nomogram to predict overall survival for patients with metastatic renal cell carcinoma.
Zheng W; Zhu W; Yu S; Li K; Ding Y; Wu Q; Tang Q; Zhao Q; Lu C; Guo C
BMC Cancer; 2020 Nov; 20(1):1066. PubMed ID: 33148204
[TBL] [Abstract][Full Text] [Related]
3. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.
Kreuzberger N; Damen JA; Trivella M; Estcourt LJ; Aldin A; Umlauff L; Vazquez-Montes MD; Wolff R; Moons KG; Monsef I; Foroutan F; Kreuzer KA; Skoetz N
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012022. PubMed ID: 32735048
[TBL] [Abstract][Full Text] [Related]
4. [Establishment and validation of a novel nomogram to predict overall survival after radical nephrectomy].
Xiong LB; Zou XP; Ning K; Luo X; Peng YL; Zhou ZH; Wang J; Li Z; Yu CP; Dong P; Guo SJ; Han H; Zhou FJ; Zhang ZL
Zhonghua Zhong Liu Za Zhi; 2023 Aug; 45(8):681-689. PubMed ID: 37580273
[No Abstract] [Full Text] [Related]
5. Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma.
Correa AF; Jegede OA; Haas NB; Flaherty KT; Pins MR; Adeniran A; Messing EM; Manola J; Wood CG; Kane CJ; Jewett MAS; Dutcher JP; DiPaola RS; Carducci MA; Uzzo RG
Eur Urol; 2021 Jul; 80(1):20-31. PubMed ID: 33707112
[TBL] [Abstract][Full Text] [Related]
6. Development and External Validation of a Novel Nomogram Predicting Cancer-specific Mortality-free Survival in Surgically Treated Papillary Renal Cell Carcinoma Patients.
Piccinelli ML; Barletta F; Tappero S; Cano Garcia C; Incesu RB; Morra S; Scheipner L; Tian Z; Luzzago S; Mistretta FA; Ferro M; Saad F; Shariat SF; Ahyai S; Longo N; Tilki D; Chun FKH; Terrone C; Briganti A; de Cobelli O; Musi G; Karakiewicz PI
Eur Urol Focus; 2023 Sep; 9(5):799-806. PubMed ID: 37024421
[TBL] [Abstract][Full Text] [Related]
7. Development and internal validation of nomograms for the prediction of postoperative survival of patients with grade 4 renal cell carcinoma (RCC).
Zhu J; Liu Z; Zhang Z; Fan Y; Chen Y; He Z; Zhou L; Jin J; Shen C; Yu W
Transl Androl Urol; 2020 Dec; 9(6):2629-2639. PubMed ID: 33457235
[TBL] [Abstract][Full Text] [Related]
8. External validation of the updated Leibovich prognostic models for clear cell and papillary renal cell carcinoma in an Asian population.
Lee HJ; Lee A; Huang HH; Lau WKO
Urol Oncol; 2019 Jun; 37(6):356.e9-356.e18. PubMed ID: 30905510
[TBL] [Abstract][Full Text] [Related]
9. Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery.
Leibovich BC; Lohse CM; Cheville JC; Zaid HB; Boorjian SA; Frank I; Thompson RH; Parker WP
Eur Urol; 2018 May; 73(5):772-780. PubMed ID: 29398265
[TBL] [Abstract][Full Text] [Related]
10. Preoperative systemic inflammation response index indicates poor prognosis in patients treated with resection of renal cell carcinoma with inferior vena cava tumor thrombus.
Lv Z; Feng HY; Wang T; Ma X; Zhang X
Urol Oncol; 2022 Apr; 40(4):167.e9-167.e19. PubMed ID: 35042663
[TBL] [Abstract][Full Text] [Related]
11. Application of Machine Learning Models to Predict Recurrence After Surgical Resection of Nonmetastatic Renal Cell Carcinoma.
Khene ZE; Bigot P; Doumerc N; Ouzaid I; Boissier R; Nouhaud FX; Albiges L; Bernhard JC; Ingels A; Borchiellini D; Kammerer-Jacquet S; Rioux-Leclercq N; Roupret M; Acosta O; De Crevoisier R; Bensalah K;
Eur Urol Oncol; 2023 Jun; 6(3):323-330. PubMed ID: 35987730
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of single-nucleotide polymorphism signature for recurrence in localised renal cell carcinoma: a retrospective analysis and multicentre validation study.
Wei JH; Feng ZH; Cao Y; Zhao HW; Chen ZH; Liao B; Wang Q; Han H; Zhang J; Xu YZ; Li B; Wu JT; Qu GM; Wang GP; Liu C; Xue W; Liu Q; Lu J; Li CX; Li PX; Zhang ZL; Yao HH; Pan YH; Chen WF; Xie D; Shi L; Gao ZL; Huang YR; Zhou FJ; Wang SG; Liu ZP; Chen W; Luo JH
Lancet Oncol; 2019 Apr; 20(4):591-600. PubMed ID: 30880070
[TBL] [Abstract][Full Text] [Related]
13. Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma.
Gatto F; Blum KA; Hosseini SS; Ghanaat M; Kashan M; Maccari F; Galeotti F; Hsieh JJ; Volpi N; Hakimi AA; Nielsen J
Eur Urol Oncol; 2018 Oct; 1(5):364-377. PubMed ID: 31158075
[TBL] [Abstract][Full Text] [Related]
14. External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Marconi L; de Bruijn R; van Werkhoven E; Beisland C; Fife K; Heidenreich A; Kapoor A; Karam J; Kauffmann C; Klatte T; Ljungberg B; Matin S; Sjoberg D; Staehler M; Stewart GD; Tanguay S; Uzzo R; Welsh S; Wood L; Wood C; Bex A
World J Urol; 2018 Dec; 36(12):1973-1980. PubMed ID: 30069581
[TBL] [Abstract][Full Text] [Related]
15. External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.
Oza B; Eisen T; Frangou E; Stewart GD; Bex A; Ritchie AWS; Kaplan R; Smith B; Davis ID; Stockler MR; Albiges L; Escudier B; Larkin J; Joniau S; Hancock B; Hermann GG; Bellmunt J; Parmar MKB; Royston P; Meade A
J Clin Oncol; 2022 Jun; 40(16):1772-1782. PubMed ID: 35213214
[TBL] [Abstract][Full Text] [Related]
16. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
17. Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation.
Correa AF; Jegede O; Haas NB; Flaherty KT; Pins MR; Messing EM; Manola J; Wood CG; Kane CJ; Jewett MAS; Dutcher JP; DiPaola RS; Carducci MA; Uzzo RG
J Clin Oncol; 2019 Aug; 37(23):2062-2071. PubMed ID: 31216227
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma.
Fan B; Wang W; Zhang X; Sun M; Wang X; Chen Z; Liu W; Wang Q; Yu N; Li X
BMC Cancer; 2019 Jun; 19(1):534. PubMed ID: 31159774
[TBL] [Abstract][Full Text] [Related]
19. Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy.
Nguyen DP; Vertosick EA; Corradi RB; Vilaseca A; Benfante NE; Touijer KA; Sjoberg DD; Russo P
Urol Oncol; 2016 Jun; 34(6):259.e1-8. PubMed ID: 26947350
[TBL] [Abstract][Full Text] [Related]
20. CXC chemokine receptor 2 is associated with postoperative recurrence and survival of patients with non-metastatic clear-cell renal cell carcinoma.
An H; Xu L; Chang Y; Zhu Y; Yang Y; Chen L; Lin Z; Xu J
Eur J Cancer; 2015 Sep; 51(14):1953-61. PubMed ID: 26188847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
